SER Similar Chart Price Prediction
The price of SER is predicted to go up 38.2%, based on the high correlation periods with GAME. The similarity of these two price pattern on the periods is 92.98%.
SER
GAME
Up: 38.2%Similarity: 92.98%
SER Revenue Forecast
SER EPS Forecast
SER Analyst's Forecast
Justin Walsh
Jones Trading
Strong Buy
2025-03-11
Price Target
$11
Upside
+137.07%
JonesResearch analyst Justin Walsh initiated coverage of Serina Therapeutics (SER) with a Buy rating and $11 price target. Serina is a drug delivery and soon-to-be clinical stage biotech company that went public via a reverse merger with AgeX Therapeutics in March of last year whose lead asset, SER-252, is being developed for the management of motor fluctuations and dyskinesia in patients with advanced Parkinson's Disease. The firm has "high confidence" that SER-252 will at least match the efficacy observed with other apomorphine delivery approaches, such as Supernus' (SUPN) recently approved Onapgo, while delivering improved tolerability and convenience, the analyst tells investors.
